Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. - Wikidata - awgldk - TriplyDB

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.

http://www.wikidata.org/entity/Q35609719

about

New advances in targeted gastric cancer treatment Children's Oncology Group's 2013 blueprint for research: bone tumors Molecular targeted therapy for the treatment of gastric cancer Potential approaches to the treatment of Ewing's sarcoma Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Dalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.Receptor tyrosine kinase gene expression profiles of Ewing sarcomas reveal ROR1 as a potential therapeutic target in metastatic disease.Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.The evolution of systemic therapy in sarcoma.Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial Vaginal Ewing Sarcoma: An Uncommon Clinical Entity in Pediatric Patients.New strategies in ewing sarcoma: lost in translation?Multimodality imaging features, metastatic pattern and clinical outcome in adult extraskeletal Ewing sarcoma: experience in 26 patients Comparative evaluation of strategies for quantifying signaling pathway proteins in Ewing sarcoma.Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma.Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis Something old, something new and something borrowed: emerging paradigm of insulin-like growth factor type 1 receptor (IGF-1R) signaling regulation PTEN deficiency mediates a reciprocal response to IGFI and mTOR inhibition.A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.Epidemiology and therapies for metastatic sarcoma IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma.Epigenetic reprogramming and re-differentiation of a Ewing sarcoma cell line Targeted therapies for advanced Ewing sarcoma family of tumors.IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy.CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma.Comprehensive analysis of published phase I/II clinical trials between 1990-2010 in osteosarcoma and Ewing sarcoma confirms limited outcomes and need for translational investment New systemic therapy options for advanced sarcomas.STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibody Molecular profiling of childhood cancer: Biomarkers and novel therapies Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.β-Arrestin-biased agonism as the central mechanism of action for insulin-like growth factor 1 receptor-targeting antibodies in Ewing's sarcoma.Advances in paediatric cancer treatment The Current and Future Therapies for Human Osteosarcoma.Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.Molecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to know

P2860

Q26738548-4D7CF497-9A83-478E-9FD9-E4224B897D96 Q27027664-AAEAC8D0-BC29-447E-B1F1-C64D9F6D62F4 Q28072433-DF1360A6-A3ED-47D5-8B35-11EAE934996A Q28072744-78885312-822F-4FA1-B7DD-F3B7AB9AD9CE Q28088432-9A0B9F93-0F71-48E8-94B5-68446E1F5DB6 Q28548425-B79A2704-F952-4333-89AE-FFC300213A22 Q30234441-685BE81A-CB9E-4E64-88FA-6474FDBC5732 Q30313824-ED5C71C4-6886-4C5D-AF51-99EAE8E09EAF Q30315828-895B5CB4-61A2-4C6F-954A-CA47F0A13108 Q33274572-FACE074E-59E7-44E4-8E6C-A766C2E92EDD Q33274710-014EC8D8-B9D8-45BD-A272-D18C648C2352 Q33275887-8BF3D6FE-332F-4979-BFC6-944D9A502F17 Q33406371-3FA4592C-EFC2-47E4-A504-CE659C9907DB Q33693504-FAD35F53-AD12-416A-BA7B-22E67F00E8C8 Q33758471-3FCEF7A8-B7A7-4681-B4C3-223F8726CF3A Q33823207-DD6AE9DD-D9D4-4B51-B4EB-F220A1A359E3 Q34105623-77F34209-3D24-43F9-8D86-D688501D7156 Q34110523-9A1B74B5-5860-4D81-B759-ACE9F3B68B1A Q34226841-B977536F-6657-45DC-9B9E-41A4CF0E9934 Q34387886-BE11A840-8E94-4E4E-B1CE-306D6CC7F376 Q34518277-BDD56A81-D059-40CF-BB58-776B9F31F55E Q34532397-8F20F9EC-708E-47FE-B137-3D31ED75FE37 Q34652142-F931DEC6-6020-4A57-9EC4-12DB5D3B2811 Q34728942-80D107CD-AE26-43E1-9F19-CCF8C3DDC6D2 Q35158389-5984CAB2-FD9C-402C-8AD6-7D603A1D5240 Q35589492-B4FD8574-61F1-4194-83FC-C42900575DD5 Q35690979-5FBD5B82-2C6E-43B5-AE9C-518C2B6C207A Q35850208-DC9FA6D9-5B0F-448F-9DBC-217B23E15ACB Q35894540-44DA71C9-E042-434D-91C8-66588AFCC475 Q35941350-5C19E1EC-FBA5-4DB6-AEA1-4B121779CDBB Q35958048-C3A70949-2D19-465F-AD99-8A565B24C833 Q36166394-9076C3F6-6E85-42DE-AD32-B0997F8B052E Q36169762-60C4148D-0107-44B7-BA07-5DF91B1C431F Q36250783-C2983263-DF48-40A9-83EF-54DC4A593500 Q36270666-A083481C-262D-47CC-89F0-E3B8882BEDBB Q36483910-3FCED33B-CFE7-4D1B-B384-38AA03D08FAE Q36508630-4C2D5B2C-F7FE-417A-A07E-FC3FD12713B0 Q36514299-3ABD3AA4-EA97-477D-BF9A-10D9134D7D65 Q36615766-E2E3BE85-60DF-495E-B25D-C460B9D28A2E Q36819466-F95C057F-6965-4B63-AC19-27000DAF4DB2

P2860

Preliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma.

http://www.wikidata.org/entity/Q35609719

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Preliminary efficacy of the an ...... with refractory Ewing sarcoma.

@ast

Preliminary efficacy of the an ...... with refractory Ewing sarcoma.

@en

type

label

Preliminary efficacy of the an ...... with refractory Ewing sarcoma.

@ast

Preliminary efficacy of the an ...... with refractory Ewing sarcoma.

@en

prefLabel

Preliminary efficacy of the an ...... with refractory Ewing sarcoma.

@ast

Preliminary efficacy of the an ...... with refractory Ewing sarcoma.

@en

P1433

Q35609719-0251CB18-562D-47DE-9A41-4238F721CC97

P1476

Q35609719-F9CC0617-A79A-4865-A55E-908EFDF51AFC

P2093

Q35609719-25BEDEC2-4CD5-4F75-ACA0-56F7E8A5B57A

Q35609719-31648C45-306C-49BF-A0C5-0565D078E2B0

Q35609719-3DBC3A5E-253D-4D01-BA5B-29722EFA7842

Q35609719-68D8B9FF-B697-4B45-B2BC-8EA3C85E0A8C

Q35609719-70CD9675-A02C-4B24-820E-2C2D934B1336

Q35609719-80EC2E8B-22C4-417B-9DFE-008014935003

Q35609719-A1DAEAC0-1E8B-4B1B-BFC0-3C5F19E8D56A

Q35609719-A88F4483-6124-49AA-BCB3-C6F91EA40D0E

Q35609719-AEB01CA7-3FFE-46A1-B296-87BA15A07F85

Q35609719-B5CCDB2C-9C6E-4C5C-9441-F991BF9250E7

P2860

Q35609719-29A58554-6AB6-41D0-BCD5-E032E72CB371

Q35609719-2DC8919A-1B6D-4F12-B035-386101CFE462

Q35609719-3A9DC459-13CB-40D6-9CB2-48FB73C29817

Q35609719-41CCDE17-CB0D-48C7-B705-9883F57D2875

Q35609719-42525011-44DF-4F6E-B36D-7B2E6D13515F

Q35609719-55579550-4530-4107-8EE0-4A961AC9995B

Q35609719-5EC7F0C3-206D-4ED6-B013-0C12244265AF

Q35609719-68ECCD60-F09D-4C44-915F-3B12649B5785

Q35609719-92C9CE22-8137-48CD-9B81-9F7DE5A4BE20

Q35609719-A538A4B0-CAED-4889-A29F-552E1404A693

P304

Q35609719-2F3356E6-0E7D-4518-A023-153A383D0D38

P31

Q35609719-048C3F5F-AB29-421D-8082-9B09E97DE310

P356

Q35609719-E0322D7A-B160-436B-9FA5-68D25565777B

P407

Q35609719-5D1049ED-FF9F-4F53-B4B8-EF79C3D7FDDD

P433

Q35609719-98E5FE5A-522F-4BEB-9CEA-12B32F69AE68

P478

Q35609719-60962624-2A82-48EF-9019-EE59555E6F24

P577

Q35609719-2CD1797D-4D81-4B2B-A22D-0D6F9CE6DB59

P698

Q35609719-F1382624-998C-4D5D-B39E-D2A802C00CF4

P921

Q35609719-841873CE-E23C-4351-8C24-BA7430ED957B

Q35609719-9DF7CE5C-3974-4C23-AED8-E28068BB5E32

Q35609719-C24B8321-3629-4B58-97F0-31629BA2FD46

P932

Q35609719-63E75FD7-414F-4005-9AC4-83CDFB115442

P356

JCO.2010.33.0670

P1433

Journal of Clinical Oncology

P1476

Preliminary efficacy of the an ...... with refractory Ewing sarcoma.

@en

P2093

Antonio Gualberto

http://www.w3.org/2001/XMLSchema#string

Birgit Geoerger

http://www.w3.org/2001/XMLSchema#string

Donghua Yin

http://www.w3.org/2001/XMLSchema#string

Heribert Juergens

http://www.w3.org/2001/XMLSchema#string

Isabelle Aerts

http://www.w3.org/2001/XMLSchema#string

Jeremy Whelan

http://www.w3.org/2001/XMLSchema#string

Luisa Paccagnella

http://www.w3.org/2001/XMLSchema#string

Mary L Hixon

http://www.w3.org/2001/XMLSchema#string

Milena Villarroel

http://www.w3.org/2001/XMLSchema#string

Najat C Daw

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin and insulin-like growth factor signalling in neoplasia

Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies

Insulin-like growth factor-I and cancer mortality in older men.

Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study

Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma.

Mechanisms of sarcoma development.

Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group

EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions.

P304

4534-4540

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.33.0670

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22025154

http://www.w3.org/2001/XMLSchema#string

P921

P932

3236653

http://www.w3.org/2001/XMLSchema#string